Skip to main content
SpringerLink
Log in

Behçet’s Syndrome and the Nervous System

  • Chapter
  • First Online:
Book cover Behçet’s Syndrome

Abstract

Patients with Behçet’s Syndrome (BS) may present with different neurological problems, which are either primary or secondary consequences of the systemic disease. The clinical and imaging evidence suggests that primary neurological involvement in BS may be divided into two major forms: The first form, seen in the majority of patients, is the parenchymal central nervous system (CNS) involvement. This is likely to be due to inflammatory small vessel disease, and may present as an acute disorder or may have a chronic progressive form. It’s named as intra-axial “neuro-Behçet’s syndrome” (NBS). The second form, which has few symptoms and a better neurological prognosis, is caused by isolated cerebral venous sinus thrombosis and presents with symptoms and signs of intracranial hypertension, and it’s named as extra-axial “neuro-Behçet’s syndrome.” These two types rarely occur in the same individual, and their pathogenesis is likely to be different. Isolated behavioral syndromes and peripheral nervous system involvement are rare, whereas a nonstructural vascular type headache is relatively common and independent from neurological involvement. Neurologic complications secondary to systemic involvement of BS such as cerebral emboli from cardiovascular complications of BS and increased intracranial pressure due to superior vena cava syndrome, as well as neurologic complications related to BS treatments such as CNS neurotoxicity with cyclosporine and peripheral neuropathy with the use of thalidomide or colchicine are considered as secondary neurological complications. Acute episodes of NBS are treated with high-dose i.v. methylprednisolone followed by an oral tapering. As the neurological involvement in this syndrome is so heterogeneous, it is difficult to predict its course and prognosis, and response to treatment. A number of immunosuppressive agents as well as the immunomodulatory agent interferon-alpha have been used for the long-term treatment of intra-axial NBS, but none of them have been shown to be specifically beneficial. The monoclonal anti-TNF alpha antibody treatment emerges as a new option for the same purpose, but further data is needed. Currently, treatment options are limited to attack and symptomatic therapies, with no evidence for the efficacy of any long-term preventive treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siva A, Altıntas A, Saip S (2004) Behçet’s syndrome and the nervous system. Curr Opin Neurol 17:347–357

    Article  PubMed  Google Scholar 

  2. Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, Hashimoto T (1997) Cerebrospinal fluid interleukin-6 in progressive Neuro-Behçet’s syndrome. Clin Immunol Immunopathol 82:12–17

    Article  PubMed  CAS  Google Scholar 

  3. Kawai M, Hirohata S (2000) Cerebrospinal fluid beta(2)-microglobulin in neuro-Behçet’s syndrome. J Neurol Sci 179:132–139

    Article  PubMed  CAS  Google Scholar 

  4. Wechsler B, Vidailhet M, Bousser MG et al (1992) Cerebral venous sinus thrombosis in Behçet’s disease: long term follow-up of 25 cases. Neurology 42:614–618

    Article  PubMed  CAS  Google Scholar 

  5. Serdaroglu P (1998) Behçet’s disease and the nervous system. J Neurol 245:197–205

    Article  PubMed  CAS  Google Scholar 

  6. Siva A, Özdogan H, Yazici H et al (1986) Headache, neuro-psychiatric and computerized tomography findings in Behçet’s syndrome. In: Lehner T, Barnes CG (eds) Recent advances in Behçet’s disease. Royal Society of Medicine Service, London, pp 247–254

    Google Scholar 

  7. International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080

    Google Scholar 

  8. Akman-Demir G, Serdaroglu P, Tasci B, The Neuro-Behçet Study Group (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. Brain 122:2171–2182

    Article  PubMed  Google Scholar 

  9. Kidd D, Steuer A, Denman AM, Rudge P (1999) Neurological complications in Behçet’s syndrome. Brain 122:2183–2194

    Article  PubMed  Google Scholar 

  10. Siva A, Kantarci OH, Saip S et al (2001) Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 248:95–103

    Article  PubMed  CAS  Google Scholar 

  11. Kural-Seyahi E, Fresko I, Seyahi N et al (2003) The long-term mortality and morbidity of Behçet’s syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60

    Article  Google Scholar 

  12. Tunc R, Saib S, Siva A, Yazici H (2004) Cerebral venous thrombosis is associated with major vessel disease in Behçet’s syndrome. Ann Rheum Dis 63:1693–1694

    Article  PubMed  CAS  Google Scholar 

  13. Al-Araji A, Kidd DP (2009) Neuro-Behçet’s disease: epidemiology, clinicalcharacteristics, and management. Lancet Neurol 8:192–204

    Article  PubMed  Google Scholar 

  14. Saadoun D, Wechsler B, Resche-Rigon M et al (2009) Cerebral venous thrombosis in Behçet’s disease. Arthritis Rheum (Arthritis Care Res) 61:518–526

    Article  CAS  Google Scholar 

  15. Yesilot N, Bahar S, Yilmazer S et al (2009) Cerebral venous thrombosis in Behçet’s disease compared to those associated with other etiologies. J Neurol 256(7):1134–1142

    Article  PubMed  CAS  Google Scholar 

  16. Houman MH, Hamzaoui-B’Chir S, Ben Ghorbel I et al (2002) Neurologic manifestations of Behçet’s disease: analysis of a series of 27 patients. Rev Med Interne 23:592–606

    Article  PubMed  CAS  Google Scholar 

  17. Siva A, Saip S (2009) The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis. J Neurol 256:513–529

    Article  PubMed  Google Scholar 

  18. Bahar S, Coban O, Gürvit H et al (1993) Spontaneus dissection of the extracranial vertebral artery with spinal subarachnoid hemorrhage in a patient with Behçet’s disease. Neuroradiology 35:352–354

    Article  PubMed  CAS  Google Scholar 

  19. Krespi Y, Akman-Demir G, Poyraz M et al (2001) Cerebral vasculitis and ischaemic stroke in Behçet’s disease: report of one case and review of the literature. Eur J Neurol 8(6):719–722

    Article  PubMed  CAS  Google Scholar 

  20. Sagduyu A, Sirin H, Oksel F et al (2002) An unusual case of Behçet’s disease presenting with bilateral internal carotid artery occlusion. J Neurol Neurosurg Psychiatry 73:343

    Article  PubMed  CAS  Google Scholar 

  21. Kizilkilic O, Albayram S et al (2003) Endovascular treatment of Behçet’s disease-associated intracranial aneurysms: report of two cases and review of the literature. Neuroradiology 45:328–334

    PubMed  Google Scholar 

  22. Aktas EG, Kaplan M, Ozveren MF (2008) Basilar artery aneurysm associated with Behçet’s Disease: a case report. Turk Neurosurg 18:35–38

    PubMed  Google Scholar 

  23. Kocer N, Islak C, Siva A et al (1999) CNS involvement in Neuro-Behçet’s syndrome: an MR study. AJNR 20:1015–1024

    PubMed  Google Scholar 

  24. Kikuchi S, Niino M, Shinpo K et al (2002) Intracranial hemorrhage in neuro-Behçet’s syndrome. Intern Med 41:692–695

    Article  PubMed  Google Scholar 

  25. Saip S, Siva A, Altıntas A et al (2005) Headache in Behçet’s syndrome. Headache 45:911–919

    Article  PubMed  Google Scholar 

  26. Monastero R, Mannino M, Lopez G et al (2002) Prevalence of headache in patients with Behçet’s disease without overt neurological involvement. Cephalalgia 23:105–108

    Article  Google Scholar 

  27. Aykutlu E, Baykan B, Akman-Demir G et al (2006) Headache in Behçet’s disease. Cephalalgia 26:180–186

    Article  PubMed  CAS  Google Scholar 

  28. Kidd D (2006) The prevalence of headache in Behçet’s syndrome. Rheumatology 45:621–623

    Article  PubMed  CAS  Google Scholar 

  29. Haghighi AB, Aflaki E, Ketabchi L (2008) The prevalence and characteristics of different types of headache in patients with Behçet’s disease, a casecontrol study. Headache 48:424–429

    Article  Google Scholar 

  30. Hirohata S (2007) Potential new therapeutic options for involvement of central nervous system in Behçet’s disease (neuro-Behçet’s syndrome). Curr Rheumatol Rev 3:297–303

    Article  CAS  Google Scholar 

  31. Oktem-Tanor O, Baykan-Kurt B, Gurvit IH et al (1999) Neuropsychological follow-up of 12 patients with neuro-Behçet’s disease. J Neurol 246:113–119

    Article  PubMed  CAS  Google Scholar 

  32. Serdaroglu P (1989) Neuromuscular manifestations in the course of Behçet’s disease. Acta Myologica 2:41–45

    Google Scholar 

  33. Namer IJ, Karabudak R, Zileli T et al (1987) Peripheral nervous system involvement in Behçet’s disease. Eur Neurol 26:235–240

    Article  PubMed  CAS  Google Scholar 

  34. Lannuzel A, Lamaury I, Charpentier D, Caparros-Lefebvre D (2002) Neurological manifestations of Behçet’s disease in a Caribbean population: clinical and imaging findings. J Neurol 249:410–418

    Article  PubMed  Google Scholar 

  35. Sarui H, Maruyama T, Ito I et al (2002) Necrotising myositis in Behçet’s disease: characteristic features on magnetic resonance imaging and a review of the literature. Ann Rheum Dis 61:751–752

    Article  PubMed  CAS  Google Scholar 

  36. Atasoy HT, Tunc TO, Unal AE et al (2007) Peripheral nervous system involvement in patients with Behçet’s disease. Neurologist 13:225–230

    Article  PubMed  Google Scholar 

  37. Al-Araji A, Sharquie K, Al-Rawi Z (2003) Prevalence and patterns of neurological involvement in Behçet’s disease: a prospective study from Iraq. J Neurol Neurosurg Psychiatry 74:608–613

    Article  PubMed  CAS  Google Scholar 

  38. Yesilot N, Shehu M, Oktem-Tanor O et al (2006) Silent neurological involvement in Behçet’s disease. Clin Exp Rheumatol 24:S65–S70

    PubMed  CAS  Google Scholar 

  39. Kececi H, Akyol M (2001) P300 in Behçet’s patients without neurological manifestations. Can J Neurol Sci 28:66–69

    PubMed  CAS  Google Scholar 

  40. Karatas GK, Onder M, Meray J (2002) Autonomic nervous system involvement in Behçet’s disease. Rheumatol Int 22:155–159

    Article  PubMed  Google Scholar 

  41. Huang WS, Chiu PY, Kao A, Tsai CH, Lee CC (2002) Decreased cerebral blood flow in neuro-Behçet’s syndrome with neuropsychiatricmanifestations and normal magnetic resonance imaging – a preliminary report. J Neuroimaging 12:355–359

    Article  PubMed  Google Scholar 

  42. Nobili F, Cutolo M, Sulli A et al (2002) Brain functional involvement by perfusion SPECT in systemic sclerosis and Behçet’s disease. Ann NY Acad Sci 966:409–414

    Article  PubMed  CAS  Google Scholar 

  43. Cengiz N, Sahin M, Onar M (2004) Correlation of clinical, MRI and Tc-99m HMPAO SPECT findings in neuro-Behçet’s disease. Cengiz N, Sahin M, Onar M. Correlation of clinical, MRI and Tc-99 m HMPAO SPECT findings in neuro-Behçet’s disease. Acta Neurol Belg 104:100–105

    PubMed  Google Scholar 

  44. Tunc T, Ortapamuk H, Naldoken S et al (2006) Subclinical neurological involvement in Behçet’s disease. Neurol India 54:408–411

    Article  PubMed  Google Scholar 

  45. Hirohata S (2008) Histopathology of central nervous system lesions in Behçet’s disease. J Neurol Sci 267:41–47

    Article  PubMed  CAS  Google Scholar 

  46. Hadfield MG, Aydin F, Lippman HR et al (1996) Neuro-Behçet’s disease. Clin Neuropathol 15:249–255

    PubMed  CAS  Google Scholar 

  47. Arai Y, Kohno S, Takahashi Y et al (2006) Autopsy case of neuro-Behçet’s disease with multifocal neutrophilic perivascular inflammation. Neuropathology 26:579–585

    Article  PubMed  Google Scholar 

  48. Kawakita H, Nishimura M, Satoh Y, Shibata N (1967) Neurological aspects of Behçet’s disease: a case report and clinico-pathological review of the literature in Japan. J Neurol Sci 5:417–438

    Article  PubMed  CAS  Google Scholar 

  49. Scardamaglia L, Desmond PM, Gonzales MF et al (2001) Behçet’s disease with cerebral vasculitis. Int Med J 31:560–561

    Article  CAS  Google Scholar 

  50. Akman-Demir G, Tuzun E, Icoz S et al (2008) Interleukin-6 in neuro-Behçet’s disease: association with disease subsets and long-term outcome. Cytokine 44:373–376

    Article  PubMed  CAS  Google Scholar 

  51. Hirohata S, Suda H, Hashimoto T (1998) Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet’s disease. J Neurol Sci 159:181–185

    Article  PubMed  CAS  Google Scholar 

  52. Kessler JA, Ludlam WH, Freidin MM et al (1993) Cytokine-induced programmed death of cultured sympathetic neurons. Neuron 11:1123–1132

    Article  PubMed  CAS  Google Scholar 

  53. Heyser CJ, Masliah E, Samimi A et al (1997) Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci USA 94:1500–1505

    Article  PubMed  CAS  Google Scholar 

  54. Gruol DL, Nelson TE (2005) Purkinje neuron physiology is altered by the inflammatory factor interlukin-6. Cerebellum 4:198–205

    Article  PubMed  CAS  Google Scholar 

  55. Gadient RA, Otten UH (1997) Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials. Prog Neurobiol 52:379–390

    Article  PubMed  CAS  Google Scholar 

  56. Saruhan-Direskeneli G, Yentur SP, Akman-Demir G et al (2003) Cytokines and chemokines in neuro-Behçet’s disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol 145:127–134

    Article  PubMed  CAS  Google Scholar 

  57. Matsuo K, Yamada K, Nakajima K, Nakagawa M (2005) Neuro-Behçet’s disease mimicking brain tumor. Am J Neuroradiol 26:650–653

    PubMed  Google Scholar 

  58. Aktas EG, Kaplan M, Ozveren MF (2008) Basilar artery aneurysm associated with Behçet’s disease: a case report. Turk Neurosurg 18:35–38

    PubMed  Google Scholar 

  59. Hisanaga K, Iwasaki Y, Itoyama Y (2005) Neuro-Sweet disease: clinical manifestations and criteria for diagnosis. Neurology 64:1756–1761

    Article  PubMed  Google Scholar 

  60. Hisanaga K (2007) Neuro-neutrophilic disease: neuro-Behçet’s disease and neuro-Sweet disease. Intern Med 46:153–154

    Article  PubMed  Google Scholar 

  61. Siva A, Fresko I (2000) Behçet’s disease. Curr Treat Options Neurol 2:435–448

    Article  PubMed  Google Scholar 

  62. Kantarci O, Siva A (2006) Behçet’s disease: diagnosis and management (Chapter 96). In: Noseworthy J (ed) Neurological therapeutics principles and practice, 2nd edn. Informa Healthcare, New York, pp 1196–1206

    Google Scholar 

  63. Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet’s disease. N Engl J Med 341:1284–1291

    Article  PubMed  CAS  Google Scholar 

  64. Kotake S, Higashi K, Yoshikawa K et al (1999) Central nervous system symptoms in patients with Behçet’s disease receiving cyclosporine therapy. Ophthalmology 106:586

    Article  PubMed  CAS  Google Scholar 

  65. Mitsui Y, Mitsui M, Urakami R et al (2005) Behçet’s disease presenting with neurological complications immediately after conversion from conventional cyclosporin A to microemulsion formulation. Intern Med 44:149–152

    Article  PubMed  Google Scholar 

  66. Kotter I, Gunaydin I, Batra M et al (2006) CNS involvement occurs more frequently in patients with Behçet’s disease under cyclosporin A than under other medications results of a retrospective analysis of 117 cases. Clin Rheumatol 25:482–486

    Article  PubMed  Google Scholar 

  67. Kikuchi H, Aramaki K, Hirohata S (2003) Low dose MTX for progressive neuro-Behçet’s disease. A follow-up study for 4 years. Adv Exp Med Biol 528:575–578

    Article  PubMed  CAS  Google Scholar 

  68. Licata G, Pinto A, Tuttolomondo A et al (2003) Anti-tumor necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet’s syndrome. Ann Rheum Dis 62:280–281

    Article  PubMed  CAS  Google Scholar 

  69. Ribi C, Sztajzel R, Delavelle J, ChizzoliniC J (2005) Efficacy of TNF a blockade in cyclophosphamide resistant neuro-Behçet’s disease. Neurol Neurosurg Psychiatry 76:1733–1735

    Article  CAS  Google Scholar 

  70. Sarwar H, McGrath H Jr, Espinoza LR (2005) Successful treatment of long-standing neuro-Behçet’s disease with infliximab in patients with refractory disease. J Rheumatol 32:181–183

    PubMed  Google Scholar 

  71. Fujikawa K, Aratake K, Kawakami A et al (2007) Successful treatment of refractory neuro-Behçet’s disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 66:136–137

    Article  PubMed  CAS  Google Scholar 

  72. Piptone N, Olivieri I, Padula A et al (2008) Infl iximab for the treatment of neuro-Behçet’s disease: a case series and review of the literature. Arthritis Rheum 59:285–290

    Article  Google Scholar 

  73. Kikuchi H, Aramaki K, Hirohata S (2008) Effect of infliximab in progressive Neuro-Behçet’s syndrome. J Neurol Sci 272:99–105

    Article  PubMed  CAS  Google Scholar 

  74. Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Behçet’s disease. Ann Rheum Dis 67:1656–1662

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Clinical Neuroimmunology Unit, Cerrahpaşa School of Medicine, University of Istanbul, Istanbul, Turkey

    Aksel Siva

Authors
  1. Aksel Siva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shunsei Hirohata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aksel Siva .

Editor information

Editors and Affiliations

  1. Hospital for Joint Diseases, Behçet's Syndrome Center, NYU Medical Center, East 20th Street 246, New York, 10003, New York, USA

    Yusuf Yazıcı

  2. , Department of Medicine, University of Istanbul, Istanbul, 34452, Turkey

    Hasan Yazıcı

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Siva, A., Hirohata, S. (2010). Behçet’s Syndrome and the Nervous System. In: Yazıcı, Y., Yazıcı, H. (eds) Behçet’s Syndrome. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-5641-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-5641-5_6

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-5640-8

  • Online ISBN: 978-1-4419-5641-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation